PBYI
PUMA BIOTECHNOLOGY, INC.
NASDAQ · Healthcare · Biotechnology · US
$10.54
−0.75%Year over year
Reported trailing growth
- Revenue
- -2.9%
- EBITDA
- -28.6%
- EBIT
- -33.9%
- EPS
- -45.3%
- Free cash flow
- -6.9%
- Operating cash flow
- -7.2%
Forward estimates
Based on analyst estimates
- Revenue
- -70.9%
- EBITDA
- -58.2%
- EPS
- -57.1%
Three-year CAGR
- Revenue
- +0.0%
- EBITDA
- +34.6%
- EBIT
- +16.3%
- Net income
- +2396.3%
- EPS
- +212.1%
- Free cash flow
- +70.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026